Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimisation of inhaler therapy for breathlessness in lung cancer patients with COPD
2010-021412-42Phase 3Completed
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Oct 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of salbutamol, tiotropium, salmeterol and fluticasone propionate in chronic obstructive pulmonary disease (COPD), bronchial carcinoma and Dyspnoea (SOB) (2 arms), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: Change in breathlessness VAS at 4 weeks. Started Oct 2010; status: completed.
02
Drugs
salbutamoltiotropiumsalmeterolfluticasone propionate
03
Conditions
chronic obstructive pulmonary disease (COPD)bronchial carcinomaDyspnoea (SOB)
Beyond the preview
Go deeper on 2010-021412-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021412-42.